LY-2624587

• Target:

  Akt|||p38 MAPK|||Apoptosis|||CXCR

• Related Pathways:

  Cytoskeletal Signaling|||Apoptosis|||PI3K/Akt/mTOR signaling|||Autophagy|||GPCR/G Protein|||MAPK|||Immunology/Inflammation

• Bioactivity:

  LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. It effectively blocks the interaction between SDF-1 and CXCR4, as well as SDF-1-induced GTP binding. LY-2624587 significantly inhibits cellular migration and induces apoptosis in human lymphoma and leukemia cells. Additionally, LY-2624587 suppresses cell signaling mediated by CXCR4 and SDF-1, including MAPK and AKT activation. This compound is utilized in research on human hematological malignancies, such as acute myeloid leukemia (AML) .

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  2125546-89-4